EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 487 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 How to Cope With Taking Long-Term Medication June 27, 2023 Cell Phone Use May Increase Risk of Breast and Thyroid Cancer,... January 7, 2021 Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in... September 4, 2024 Load more HOT NEWS Bringing a Piece of Home to the Hospital Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis
